60469-70-7

Basic information

• Product Name: tert-butylamine hydrobromide
• Synonyms: tert-butylamine hydrobromide;Nsc225071;tert-Butylamine Hydrobromide
• CAS NO: 60469-70-7
• Molecular Formula: Br*C₄H₁₂N
• Molecular Weight: 154.04878
• EINECS: 262-253-5
• Mol File: 60469-70-7.mol

Chemical Properties

• Boiling Point: 44.4°C at 760 mmHg
• Appearance: /
• Vapor Pressure: 363mmHg at 25°C
• Water Solubility: Soluble in water
• CAS DataBase Reference: tert-butylamine hydrobromide(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butylamine hydrobromide(60469-70-7)
• EPA Substance Registry System: tert-butylamine hydrobromide(60469-70-7)

Safety Data

• Hazardous Substances Data: 60469-70-7(Hazardous Substances Data)

Usage

Uses

Used in the Photovoltaic Industry:
Tert-butylamine hydrobromide is used as a structural modifier for perovskite materials to improve their solubility and stability. The application reason is that the presence of the tert-butyl bulky group in tBABr helps to make the perovskite structures less sensitive to moisture, which is a significant factor in the degradation of perovskite solar cells.
Used in the Electronics Industry:
Tert-butylamine hydrobromide is used as a component in the development of perovskite-based electronic devices, such as light-emitting diodes (LEDs) and transistors. The application reason is that the enhanced crystallinity and stability provided by tBABr can lead to improved device performance and longer operational lifetimes.
Used in the Material Science Research:
Tert-butylamine hydrobromide is used as a precursor in the synthesis of plate-like 2D-phase crystallites for perovskite structures. The application reason is that the presence of bulky alkyl groups in the perovskite structure, as provided by tBABr, can significantly enhance the crystallinity of the resulting materials, which is crucial for their performance in various applications.

Purification Methods

Recrystallise the salt several times from absolute EtOH or by dissolving in absolute EtOH and adding Et2O slowly to crystallise the salt. Dry it thoroughly at 105o. [IR: Chenon & Sandorfy Can J Chem 36 1181 1958, Beilstein 4 IV 659.]

InChI:InChI=1/C4H11N.BrH/c1-4(2,3)5;/h5H2,1-3H3;1H

Upstream product

• 506-68-3 bromocyane 
• 75-64-9 tert-butylamine 

Downstream Products

• 104679-53-0 4-(2',5'-dimethoxy-3',4',6'-trimethylphenyl)-2-methyl-2-butenol 

Relevant articles and documents

A novel one-pot synthesis of hydroximoyl chlorides and 2-isoxazolines using N-tert-butyl-N-chlorocyanamide

Treatment of aldoximes with N-tert-butyl-N-chlorocyanamide gave hydroximoyl chlorides in quantitative yields in less than a minute, which on dehydrohalogenation in the presence of triethylamine gave the corresponding nitrile oxides. The nitrile oxides underwent 1,3-dipolar addition to dipolarophiles and gave 2-isoxazolines in excellent yields under mild conditions.

Method for improving the absorption and effectiveness of a catecholamine compound

A catecholamine compound is converted to a new mono O-phosphate ester derivative thereof which exhibit improved absorption and effectiveness.

Amines useful as brain imaging agents

Certain radioiodine containing amines useful as brain imaging agents are disclosed. The compounds of the invention are represented by the formula STR1 wherein I is a radioisotope of iodine with I-123 being preferred, R is lower alkyl or halogen, R1 and R2 are the same or different and are selected from the group consisting of hydrogen and lower alkyl, R3 and R4 are the same or different and are selected from the group consisting of hydrogen, alkyl, aryl, substituted aryl, aralkyl, substituted aralkyl and substituted carbamoyl methyl or R3 and R4 taken together with the nitrogen to which they are attached form a 5- or 6-membered ring which may be substituted with one or more lower alkyl groups, x is 0 to 4, y is 0 to 3 and z is 0 or 1 and pharmaceutically acceptable acid addition salts thereof.

Process for interrupting pregnancy with sulfonamidoaminophene interceptive agents

A process for interrupting pregnancy is disclosed which comprises administration to a mammal an interceptive agent selected from a group of sulfonamidoaminophenones. Illustrative of sulfonamidoaminophenone interceptive agents useful in the process of the present invention for interrupting pregnancy are 4'-(N,N-diethylalanyl)-methanesulfonanilide and 4'-[N-α,α -dimethylphenethyl)alanyl]methanesulfonanilide.